Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit

被引:7
|
作者
Levy, Jerrold H. [1 ]
Ghadimi, Kamrouz [1 ]
Quinones, Quintin J. [1 ]
Bartz, Raquel R. [1 ]
Welsby, Ian [1 ]
机构
[1] Duke Univ, Dept Anesthesiol, Div Cardiothorac Anesthesiol, Durham, NC USA
关键词
Antifibrinolytics; Apixaban; Bleeding; Dabigatran; Factor concentrates; Factor Vlla; Fibrinogen; Hemorrhage; Prothrombin complex concentrates; Rivaroxaban; ACTIVATED FACTOR-VII; RECOMBINANT FACTOR VIIA; FIBRINOGEN CONCENTRATE; TRANEXAMIC ACID; CARDIAC-SURGERY; POLYMERIZATION ASSAYS; REPLACEMENT THERAPY; HEMOSTATIC SYSTEM; MANAGEMENT; TRAUMA;
D O I
10.1016/j.tmrv.2017.04.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients who are critically ill following surgical or traumatic injury often present with coagulopathy as a component of the complex multisystem dysfunction that clinicians must rapidly diagnose and treat in the intensive care environment. Failure to recognize coagulopathy while volume resuscitation with crystalloid or colloid takes place, or an unbalanced transfusion strategy focused on packed red blood cell transfusion can all significantly worsen coagulopathy, leading to increased transfusion requirements and poor outcomes. Even an optimized transfusion strategy directed at correcting coagulopathy and maintaining clotting factor levels carries the risk of a number of transfusion reactions including transfusion-related acute lung injury, transfusion-related circulatory overload, anaphylaxis, and septic shock. A number of adjunctive strategies can be used either to augment a balanced transfusion approach or as alternatives to blood component therapy. Coupled with an appropriate and timely laboratory testing, this approach can quickly diagnose a patient's specific coagulopathy and work to correct it as quickly as possible, minimizing the requirement of blood transfusion and the pathophysiologic effects of excessive bleeding and fibrinolysis. We will review the literature supporting this approach and provide insight into how these approaches can be best used to care for bleeding patients in the intensive care unit. Finally, the increasing use of several novel oral anticoagulants, novel antiplatelet drugs, and low-molecular weight heparin to clinical practice has complicated the care of the coagulopathic patient when these drugs are involved. Many clinicians familiar with heparin and warfarin reversal are not familiar with the optimal way to reverse the action of these new drugs. Patients treated with these drugs for a wide variety of conditions including atrial fibrillation, stroke, coronary artery stent, deep venous thrombosis, and pulmonary embolism will present for emergency surgery and will require management of pharmacologically induced postoperative coagulopathy. We will discuss optimized strategies for reversal of these agents and strategies that are currently under development. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:258 / 263
页数:6
相关论文
共 50 条
  • [1] Treatment of critical bleeding in the future intensive care unit
    L. T. Goodnough
    Intensive Care Medicine, 2002, 28 : s221 - s221
  • [2] Treatment of critical bleeding in the future intensive care unit
    Goodnough, LT
    INTENSIVE CARE MEDICINE, 2002, 28 (Suppl 2) : S221 - S221
  • [3] Blood Component Transfusion in Tertiary Care Neonatal Intensive Care Unit and Neonatal Intermediate Care Unit: An Audit
    Amrutiya, Rahulkumar J.
    Mungala, Bhavdeep M.
    Patel, Viral T.
    Ganjiwale, Jaishree D.
    Nimbalkar, Somashekhar M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (08)
  • [4] Management of gastrointestinal bleeding in the intensive care unit
    Braun, G.
    GASTROENTEROLOGE, 2020, 15 (01): : 34 - 40
  • [5] Blood component therapy in neonates in a neonatal intensive care unit of northern India
    Kaur, Avneet
    Dhir, Shashi Kant
    Kaur, Gurmeet
    Gupta, Manish
    Batta, Meenal
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2015, 3 : S38 - S42
  • [6] Complications of Emerging Oncology Therapies Requiring Treatment in the Pediatric Intensive Care Unit
    Killinger J.S.
    Hurley C.
    Wasserman E.
    McArthur J.
    Current Pediatrics Reports, 2017, 5 (4) : 220 - 227
  • [7] Impact of a blood transfusion protocol for non-bleeding patients in the intensive care unit
    Englert, JA
    Matchett, SC
    Baker, K
    Wasser, T
    Mundt, KL
    Carver, B
    CRITICAL CARE MEDICINE, 2001, 29 (12) : A157 - A157
  • [8] Blood and component use in intensive care
    Boralessa, H
    Rao, M
    Soni, N
    Goldhill, D
    Brett, S
    Morgan, C
    Boralessa, H
    Watson, D
    Contereras, M
    BRITISH JOURNAL OF ANAESTHESIA, 2001, 87 (02) : 347P - 347P
  • [9] Blood purification in the intensive care unit
    Ponikvar, R
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 : 63 - 67
  • [10] BLOOD SAMPLING ON THE INTENSIVE CARE UNIT
    Packer, M. E.
    Thorne, C. J.
    Arora, N.
    INTENSIVE CARE MEDICINE, 2014, 40 : S262 - S263